• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

围手术期化疗可提高局部晚期弥漫性胃癌患者的生存率。

Perioperative chemotherapy improves survival of patients with locally advanced diffuse gastric cancer.

作者信息

Li Ze-Feng, Li Zheng, Zhang Xiao-Jie, Sun Chong-Yuan, Fei He, Du Chun-Xia, Guo Chun-Guang, Zhao Dong-Bing

机构信息

Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

出版信息

World J Gastrointest Surg. 2024 Sep 27;16(9):2878-2892. doi: 10.4240/wjgs.v16.i9.2878.

DOI:10.4240/wjgs.v16.i9.2878
PMID:39351555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11438797/
Abstract

BACKGROUND

Whether patients with diffuse gastric cancer, which is insensitive to chemotherapy, can benefit from neoadjuvant or adjuvant chemotherapy has long been controversial.

AIM

To investigate whether perioperative chemotherapy can improve survival of patients with locally advanced diffuse gastric cancer.

METHODS

A total of 2684 patients with locally advanced diffuse gastric cancer from 18 population-based cancer registries in the United States were analyzed.

RESULTS

Compared with surgery alone, perioperative chemotherapy improved the prognosis of patients with locally advanced gastric cancer. Before stabilized inverse probability of treatment weighting (IPTW), the median overall survival (OS) times were 40.0 months and 13.0 months ( < 0.001), respectively. After IPTW, the median OS times were 33.0 months and 17.0 months ( < 0.001), respectively. Neoadjuvant chemotherapy did not improve the prognosis of patients with locally advanced gastric cancer compared with adjuvant chemotherapy after IPTW. After IPTW, the median OS times were 38.0 months in the neoadjuvant chemotherapy group and 42.0 months in the adjuvant chemotherapy group ( = 0.472).

CONCLUSION

Patients with diffuse gastric cancer can benefit from perioperative chemotherapy. There was no significant difference in survival between patients who received neoadjuvant chemotherapy and those who received adjuvant chemotherapy.

摘要

背景

对化疗不敏感的弥漫性胃癌患者能否从新辅助化疗或辅助化疗中获益，长期以来一直存在争议。

目的

探讨围手术期化疗能否提高局部进展期弥漫性胃癌患者的生存率。

方法

分析了来自美国18个基于人群的癌症登记处的2684例局部进展期弥漫性胃癌患者。

结果

与单纯手术相比，围手术期化疗改善了局部进展期胃癌患者的预后。在稳定的逆概率处理加权（IPTW）之前，中位总生存期（OS）分别为40.0个月和13.0个月（<0.001）。IPTW后，中位OS分别为33.0个月和17.0个月（<0.001）。与IPTW后的辅助化疗相比，新辅助化疗并未改善局部进展期胃癌患者的预后。IPTW后，新辅助化疗组的中位OS为38.0个月，辅助化疗组为42.0个月（=0.472）。

结论

弥漫性胃癌患者可从围手术期化疗中获益。接受新辅助化疗和辅助化疗的患者在生存率上无显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/f77487b8bebe/WJGS-16-2878-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/4e1407a61d42/WJGS-16-2878-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/55971a61d030/WJGS-16-2878-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/c321ee3945e2/WJGS-16-2878-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/72e8f919abee/WJGS-16-2878-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/f77487b8bebe/WJGS-16-2878-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/4e1407a61d42/WJGS-16-2878-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/55971a61d030/WJGS-16-2878-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/c321ee3945e2/WJGS-16-2878-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/72e8f919abee/WJGS-16-2878-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d4/11438797/f77487b8bebe/WJGS-16-2878-g005.jpg

相似文献

1
Perioperative chemotherapy improves survival of patients with locally advanced diffuse gastric cancer.围手术期化疗可提高局部晚期弥漫性胃癌患者的生存率。
World J Gastrointest Surg. 2024 Sep 27;16(9):2878-2892. doi: 10.4240/wjgs.v16.i9.2878.
2
[A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].基于真实世界数据的胃癌围手术期化疗多中心回顾性研究
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 May 25;24(5):403-412. doi: 10.3760/cma.j.cn.441530-20200111-00014.
3
Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.局部晚期胃食管结合部腺癌新辅助放化疗或化疗后的预后。
Br J Surg. 2021 Nov 11;108(11):1332-1340. doi: 10.1093/bjs/znab228.
4
[Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].奥沙利铂联合卡培他滨或奥沙利铂联合S-1新辅助化疗治疗进展期胃癌的安全性和有效性
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):138-144. doi: 10.3760/cma.j.cn.441530-20200721-00433.
5
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.新辅助和辅助帕博利珠单抗联合化疗治疗局部晚期胃或胃食管交界癌（KEYNOTE-585）：多中心、双盲、随机 3 期研究的中期分析。
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
6
[Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].奥沙利铂联合S-1辅助化疗用于D2淋巴结清扫术后局部进展期胃癌患者的安全性和疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):145-152. doi: 10.3760/cma.j.cn.441530-20201016-00561.
7
Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy: A Retrospective Cohort Study.局部晚期 MSI 高胃癌患者接受围手术期化疗的生存情况：一项回顾性队列研究。
Ann Surg. 2023 May 1;277(5):798-805. doi: 10.1097/SLA.0000000000005501. Epub 2022 Jun 29.
8
Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Where we Stand; An Italian Single Center Perspective.局部进展期胃癌的新辅助化疗：现状分析；来自意大利单中心的观点。
In Vivo. 2021 Nov-Dec;35(6):3459-3466. doi: 10.21873/invivo.12646.
9
The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.一项前瞻性、多中心、随机、对照 III 期研究方案，旨在评估不同周期奥沙利铂联合 S-1（SOX）作为局部晚期胃癌新辅助化疗的疗效：RESONANCE-II 试验。
BMC Cancer. 2021 Jan 5;21(1):20. doi: 10.1186/s12885-020-07764-7.
10
Neoadjuvant Chemotherapy Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched Analysis.新辅助化疗与直接手术治疗伴浆膜侵犯的局部进展期胃癌（cT4NxM0）：一项倾向评分匹配分析
Front Oncol. 2021 Aug 23;11:718556. doi: 10.3389/fonc.2021.718556. eCollection 2021.

引用本文的文献

1
Perioperative chemotherapy strategies in diffuse gastric cancer.弥漫性胃癌的围手术期化疗策略
World J Gastrointest Surg. 2025 Jan 27;17(1):101326. doi: 10.4240/wjgs.v17.i1.101326.

本文引用的文献

1
Multimodal Therapy Versus Primary Surgery for Gastric and Gastroesophageal Junction Diffuse Type Carcinoma, with a Focus on Signet Ring Cell Carcinoma: A Nationwide Study.多模态治疗与原发性手术治疗胃及胃食管交界处弥漫型癌，重点为印戒细胞癌：一项全国性研究。
Ann Surg Oncol. 2024 Mar;31(3):1760-1772. doi: 10.1245/s10434-023-14690-y. Epub 2023 Dec 21.
2
Does the ypTNM-stage adequately predict long-term survival rates in gastric cancer patients receiving neoadjuvant chemotherapy followed by radical resection?ypTNM分期能否充分预测接受新辅助化疗后行根治性切除术的胃癌患者的长期生存率？
Acta Oncol. 2023 Dec;62(12):1846-1853. doi: 10.1080/0284186X.2023.2274480. Epub 2023 Nov 25.
3
UICC Staging after Neoadjuvant/Perioperative Chemotherapy Reveals No Significant Survival Differences Compared to Primary Surgery for Locally Advanced Gastric Cancer.
与局部进展期胃癌的初次手术相比，新辅助/围手术期化疗后的 UICC 分期显示生存率无显著差异。
Cancers (Basel). 2022 Dec 14;14(24):6169. doi: 10.3390/cancers14246169.
4
Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma.原发性肿瘤切除可提高IV期胃神经内分泌癌患者的生存率。
Front Oncol. 2022 Jul 14;12:930491. doi: 10.3389/fonc.2022.930491. eCollection 2022.
5
The dawn of precision medicine in diffuse-type gastric cancer.弥漫型胃癌精准医学的曙光。
Ther Adv Med Oncol. 2022 Mar 8;14:17588359221083049. doi: 10.1177/17588359221083049. eCollection 2022.
6
The Discordance of Clinical and Pathologic Staging in Locally Advanced Gastric Adenocarcinoma.局部进展期胃腺癌临床分期与病理分期的不相符。
J Gastrointest Surg. 2021 Jun;25(6):1363-1369. doi: 10.1007/s11605-021-04993-4. Epub 2021 Apr 12.
7
Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.劳伦分类法在局部晚期胃癌或胃食管交界癌新辅助/围手术期化疗患者中的意义——来自德国一个大型单中心队列的分析
Cancers (Basel). 2021 Jan 14;13(2):290. doi: 10.3390/cancers13020290.
8
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.胃切除术联合或不联合新辅助 S-1 顺铂治疗 4 型或大型 3 型胃癌（JCOG0501）：一项开放标签、3 期、随机对照临床试验。
Gastric Cancer. 2021 Mar;24(2):492-502. doi: 10.1007/s10120-020-01136-7. Epub 2020 Nov 16.
9
A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer.一项关于在为胃癌开辅助或姑息化疗处方时考虑劳伦分型证据的队列研究和荟萃分析。
Ther Adv Med Oncol. 2020 Jul 23;12:1758835920930359. doi: 10.1177/1758835920930359. eCollection 2020.
10
A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.一项基于人群的研究，针对的是 1989 年至 2015 年间荷兰的食管和胃的肠型和弥漫型腺癌。
Eur J Cancer. 2020 May;130:23-31. doi: 10.1016/j.ejca.2020.02.017. Epub 2020 Mar 11.